
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc. reported a notable gross margin of 71.6%, reflecting a significant increase of 980 basis points year-over-year, surpassing the consensus estimate. The company achieved revenue of $28.5 million from its Light Adjustable Lens (LAL) product, representing a robust growth of 60%, while the Light Delivery Device (LDD) revenue of $10.7 million also showed a steady 7% increase. The positive outlook is supported by expectations of sustained double-digit growth fueled by increased utilization rates and expansion of the LDD installed base, alongside potential margin improvements from favorable product mix dynamics.
Bears say
RxSight Inc. has reported a significant deceleration in light adjustable lens (LAL) utilization growth, which fell to +9% year-over-year in 4Q24, compared to a range of +17%-22% in the previous five quarters, indicating a potential weakening in the company’s market position. Additionally, the U.S. intraocular lens (IOL) market appears to be experiencing stagnation or decline, influenced by increased competition and deteriorating end market conditions, which may adversely affect future sales. The company's lowered earnings per share (EPS) estimates for 2025 and 2026, alongside concerns regarding profitability, limited adoption of their technology, and potential dilution from financing, contribute to an overall negative outlook on RxSight’s stock.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares